Moreover, because MDM4 has also p53-independent oncogenic activities [20,34,35,36], targeting MDM4 splicing to prevent MDM4-FL expression in tumor cells may also present an important advantage over other strategies that are only aimed at preventing MDM4/p53 interaction. Here, TP53 is linked to neoplasm.